Abstract
The aim of this study was to investigate whether there was a particular hepatitis B virus (HBV) X protein (HBx) mutant associated with Taiwanese patients with hepatocellular carcinoma (HCC). Initially, the entire coding region of HBx gene from the serum samples of 14 Taiwanese patients were sequenced. A novel mutant, HBx-A31, was preferentially found in patients with HCC. Sera from 67 patients with HCC and 100 patients with chronic hepatitis B were thus subjected for codon 31 analysis using a dual amplification created restriction site method. HBx-A31 was detected more frequently in patients with HCC (52% versus 12%; P<0.001) and in patients with liver cirrhosis (44% versus 6%; P<0.001). Site directed mutagenesis experiment revealed that HBx-A31 was less effective in transactivating HBV enhancer I-X promoter complex, less efficient in supporting HBV replication, and less potent in enhancing TNF-α induced increment of CPP32/caspase 3 activities in HepG2 cells. In conclusion, a prevalent HBx mutant was identified in Taiwanese patients with hepatocellular carcinoma. Development of this mutant might represent a strategy of the virus to escape immune surveillance and thus contribute to the process of multiple-step hepatocarcinogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Beasley RP, Hwang LY, Lin CC and Chien CS. . 1981 Lancet 2: 1129–1133.
Becker SA, Lee T, Butel JS and Slagle BL. . 1998 J. Virol. 72: 266–272.
Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL and Palmiter RD. . 1989 Cell 59: 1145–1156.
Chu CM, Yeh CT, Chiu CT, Sheen IS and Liaw YF. . 1996 J. Clin. Microbiol. 34: 1815–1818.
Dopheide TA and Azad AA. . 1996 J. Gen. Virol. 77: 173–176.
Dunsford HA, Sell S and Chisari FV. . 1990 Cancer Res. 50: 3400–3407.
Feitelson M. . 1992 Clin. Microbiol. Rev. 5: 275–301.
Feitelson MA, Duan LX, Guo J and Blumberg BS. . 1995 Gastroenterology 108: 1810–1819.
Feitelson MA, Zhu M, Duan LX and London WT. . 1993 Oncogene 8: 1109–1117.
Ganem D and Varmus HE. . 1987 Ann. Rev. Biochem. 56: 651–693.
Gottlob K, Fulco M, Levrero M and Graessmann A. . 1998a J. Biol. Chem. 273: 33347–33353.
Gottlob K, Pagano S, Levrero M and Graessmann A. . 1998b Cancer Res. 58: 8566–8570.
Greenblatt MS, Feitelson MA, Zhu M, Bennett WP, Welsh JA, Jones R, Borkowski A and Harris CC. . 1997 Cancer Res. 57: 426–432.
Hsia CC, Nakashima Y and Tabor E. . 1997 Biochem. Biophys. Res. Commun. 241: 726–729.
Kim CM, Koike K, Saito I, Miyamura T and Jay G. . 1991 Nature 351: 317–320.
Kim H, Lee H and Yun Y. . 1998 J. Biol. Chem. 273: 381–385.
Klein NP and Schneider RJ. . 1997 Mol. Cell. Biol. 17: 6427–6436.
Lee TH, Finegold MJ, Shen RF, DeMayo JL, Woo SLC and Butel JS. . 1990 J. Virol. 64: 5939–5947.
Lee YH and Yun Y. . 1998 J. Biol. Chem. 273: 25510–25515.
Liaw YF, Tai DI, Chu CM and Chen TJ. . 1988 Hepatology 8: 493–496.
Liaw YF. . 1994 Viral Hepatitis and Liver Disease: Viral Hepatitis in Taiwan: Status in the 1990s. Nishioka K, Suzuki H, Mishiro S and Oda T (eds). Springer-Verlag: Tokyo pp. 419–421.
Lucito R and Schneider RJ. . 1992 J. Virol. 66: 983–991.
Murakami S, Cheong JH and Kaneko S. . 1994 J. Biol. Chem. 269: 15118–15123.
Qadri I, Ferrari ME and Siddiqui A. . 1996 J. Biol. Chem. 271: 15443–15450.
Ohaki Y, Misugi K, Sasaki Y and Tsunoda A. . 1983 Cancer 51: 822–828.
Robinson WS. . 1994 Annu. Rev. Med. 45: 297–323.
Rossner MT. . 1992 J. Med. Virol. 36: 101–117.
Schuster R, Gerlich WH and Schaefer S. . 2000 Oncogene 19: 1173–1180.
Su F and Schneider RJ. . 1997 Proc. Natl. Acad. Sci. USA 94: 8744–8749.
Szmuness W. . 1979 Prog. Med. Virol. 24: 40–69.
Tai DI, Tsai SL, Chen YM, Chuang YL, Peng CY, Sheen IS, Yeh CT, Chang KS, Huang SN, Kuo GC and Liaw YF. . 2000 Hepatology 31: 656–664.
Tiollais P, Pourcel C and Dejean A. . 1985 Nature 317: 489–495.
Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Sturzbecher HW, Hoeijmakers JH and Harris CC. . 1995 Cancer Res. 55: 6012–6016.
Wu JY, Zhou ZY, Judd A, Cartwright CA and Robinson WS. . 1990 Cell 63: 687–695.
Yeh CT, Shyu WC, Sheen IS, Chu CM and Liaw YF. . 1997 J. Virol. Methods 65: 219–226.
Yeh CT, Chiu HT, Chu CM and Liaw YF. . 1998 J. Med. Virol. 55: 42–50.
Yeh CT, Chien RN, Chu CM and Liaw YF. . 2000a Hepatology 31: 1318–1326.
Yeh CT, Sheen IS, Chen TC, Hsieh SY, Chu CM and Liaw YF. . 2000b J. Hepatol. 32: 829–836.
Yen TSB. . 1996 J. Biomed. Sci. 3: 20–30.
Acknowledgements
This study is supported by grants from Chang Gung Medical Research Council (CMRP 605/996) and National Science Council, Taiwan (NSC 89-2315-B-182-003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yeh, CT., Shen, CH., Tai, DI. et al. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene 19, 5213–5220 (2000). https://doi.org/10.1038/sj.onc.1203903
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203903
Keywords
This article is cited by
-
Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression
Hepatology International (2020)
-
Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
Targeted Oncology (2017)
-
Molecular characterization of hepatitis B virus X gene in chronic hepatitis B patients
Virology Journal (2012)
-
Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection
Current Hepatitis Reports (2011)
-
Hepatitis B virus X gene and hepatocarcinogenesis
Journal of Gastroenterology (2011)